3 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMORecruiting
The aims of this study are to observe the effectiveness of oral vitamin D supplementation on vitamin D status and muscle performance in vitamin D-deficient alcoholics during two different vitamin D treatment strategies (VIDIO and CAU).
Approved WMOCompleted
To determine the safety, tolerability and pharmacokinetics of an 18-hour i.v. infusion of CLR325 in stable heart failure patients.